ArticleMolecular and cellular pediatrics2026
Acquired hypothalamic obesity as α-MSH deficiency syndrome: a paradigm shift with therapeutic impact.
Article in Molecular and cellular pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Recent findings by Miller et al. ( https://doi.org/10.1056/NEJMoa2512275 ) suggest a fundamental shift in the understanding of acquired hypothalamic obesity (aHO), proposing that this condition should be viewed as an α-melanocyte-stimulating hormone (α-MSH) deficiency syndrome. Building on these observations, we discuss the proposed underlying pathophysiological mechanisms and argue that aHO can be conceptualized as an injury-induced loss of melanocortin tone, analogous to an α-MSH deficiency. The marked clinical response to setmelanotide in affected individuals indicates that downstream melanocortin-4 receptor (MC4R)-dependent pathways remain functionally intact, supporting the concept of a hormone deficiency-like state. We further explore the implications of this paradigm change, highlighting how this new framework may fundamentally change the diagnosis and management of patients with aHO.
Identifiers
42878773What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.